Skip to main content

Table 1 Treatment of subcutaneous heterotopic human pancreatic BxPC-3 tumors in nude mice

From: Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer

Treatment groups

Completion of treatment

Tumor volume (mm3)

Tumor weight (g)

Body weight (g)

Mean

Range

Mean

Range

Mean

Range

Control

5/8a

816

524–999

596

373–790

26

24–28

IFN-β

7/8a

660

281–1370

507

161–852

26

24–28

Gemcitabine

5/7a + b

745

402–1187

628

166–1121

25

24–27

IFN-β + gemcitabine

6/8

447c

213–572

492

161–958

26

24–28

  1. a Number of mice that completed 4 weeks of treatment. Mice were sacrificed before the end of treatment if the wellbeing of the animal could not be maintained (in all these mice this was due to ulceration of the tumor)
  2. b One mice died before the start of the treatment
  3. c P < 0.05 versus control